- Home
- STHO vs CRDL Comparison
STHO vs CRDL Comparison
Compare STHO & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STHO
- CRDL
- Stock Information
- Founded
- STHO N/A
- CRDL 2017
- Country
- STHO United States
- CRDL Canada
- Employees
- STHO N/A
- CRDL N/A
- Industry
- STHO Real Estate
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STHO Real Estate
- CRDL Health Care
- Exchange
- STHO Nasdaq
- CRDL Nasdaq
- Market Cap
- STHO 153.3M
- CRDL 142.5M
- IPO Year
- STHO N/A
- CRDL N/A
- Fundamental
- Price
- STHO $11.21
- CRDL $1.58
- Analyst Decision
- STHO
- CRDL Strong Buy
- Analyst Count
- STHO 0
- CRDL 3
- Target Price
- STHO N/A
- CRDL $9.00
- AVG Volume (30 Days)
- STHO 37.1K
- CRDL 421.9K
- Earning Date
- STHO 11-05-2024
- CRDL 11-14-2024
- Dividend Yield
- STHO N/A
- CRDL N/A
- EPS Growth
- STHO N/A
- CRDL N/A
- EPS
- STHO 6.15
- CRDL N/A
- Revenue
- STHO $117,752,000.00
- CRDL N/A
- Revenue This Year
- STHO N/A
- CRDL N/A
- Revenue Next Year
- STHO N/A
- CRDL N/A
- P/E Ratio
- STHO $1.82
- CRDL N/A
- Revenue Growth
- STHO 13.35
- CRDL N/A
- 52 Week Low
- STHO $11.02
- CRDL $0.79
- 52 Week High
- STHO $15.31
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- STHO 26.82
- CRDL 30.69
- Support Level
- STHO $11.02
- CRDL $1.83
- Resistance Level
- STHO $12.44
- CRDL $1.92
- Average True Range (ATR)
- STHO 0.37
- CRDL 0.15
- MACD
- STHO -0.07
- CRDL -0.04
- Stochastic Oscillator
- STHO 12.84
- CRDL 12.00
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. It focuses on realizing value for shareholders from the legacy portfolio by maximizing cash flows through active asset management and asset sales.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.